J-Pharma and Uniphar Advance First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer
核心洞察
J-Pharma and Uniphar (搜索) announced FDA alignment and advancement of nanvuranlat (JPH203), a first-in-class LAT1 inhibitor, into a global Phase 3 study for second-line biliary tract cancer (搜索).
Initial patients have been enrolled and randomized in the global study, which builds on Phase 1 and Phase 2 data from Japan showing encouraging efficacy and safety signals.
The strategic partnership with Uniphar (搜索) Development enabled a targeted regulatory strategy that bypassed the need for an additional Phase 2 study before Phase 3.
J-Pharma Co., Ltd., a Japan-based clinical-stage biotechnology company, and Uniphar (搜索), an international healthcare services group headquartered in Dublin, have jointly announced that the novel LAT1 inhibitor nanvuranlat (JPH203) has advanced into global Phase 3 clinical development for second-line biliary tract cancer (搜索). The milestone follows alignment with the U.S. Food and Drug Administration (FDA), and the first patients have now been enrolled and randomized in the global study.
The program represents a significant step for a therapy targeting amino acid transport mechanisms critical to tumor growth, an area of substantial unmet medical need.
Scientific Foundation and Mechanism of Action
Nanvuranlat is a selective small-molecule inhibitor of LAT1 (SLC7A5), a solute carrier transporter that mediates the uptake of essential amino acids required for cell growth. LAT1 is highly expressed in many cancers, and its inhibition aims to target a fundamental metabolic dependency of cancer cells without relying on a specific genetic mutation.
The scientific foundation traces back to Dr. Hitoshi Endou, founder of J-Pharma and Professor Emeritus of Kyorin University, who originally identified LAT1 as a therapeutic target. Building on this discovery, J-Pharma translated LAT1 biology into a therapeutic approach and discovered nanvuranlat.
By blocking essential amino acid uptake, nanvuranlat suppresses mTORC1 signaling and protein synthesis, thereby restricting tumor growth. J-Pharma is, to its knowledge, currently the only company advancing LAT1 inhibitors in clinical trials.
Clinical Development Pathway
In Phase 1 and Phase 2 studies conducted in Japan, J-Pharma demonstrated encouraging efficacy and safety signals in biliary tract cancer (搜索). In a randomized Phase 2 study in previously treated biliary tract cancer, nanvuranlat significantly improved progression-free survival versus placebo and demonstrated an acceptable safety profile.
These data supported FDA agreement to advance directly to a global Phase 3 study. Central to this milestone was the strategic partnership between J-Pharma and Uniphar (搜索) Development, Uniphar's regulatory and clinical development division, which enabled a targeted regulatory engagement strategy that bypassed the need for an additional Phase 2 study.
"Reaching Phase 3 with FDA alignment is a defining milestone for J-Pharma and, more importantly, for the patients with biliary tract cancer (搜索) who urgently need new options," said Max Yoshitake, President & CEO of J-Pharma. "Biliary tract cancer remains an area of significant unmet medical need worldwide, and we believe that bringing a new therapy to patients as quickly as possible carries major social significance."
Global Phase 3 Study Underway
J-Pharma and Uniphar (搜索) Development are jointly managing the Phase 3 study, with Uniphar Development also serving as J-Pharma's U.S. agent with the FDA. The program's advancement into Phase 3 has helped underpin investor confidence, contributing to J-Pharma's successful completion of its initial public offering (IPO) on the Tokyo Stock Exchange in March 2026.
Chuck Finn, PhD, Chief Scientific and Development Officer at Uniphar (搜索) Development, commented: "This collaboration demonstrates the power of an integrated regulatory and development approach. Uniphar's extensive regulatory, oncology, and development expertise combined with J-Pharma's scientific vision and development discipline, plus CEO Max Yoshitake's global development experience, have been important factors in moving the program from data reassessment and FDA engagement to active Phase 3 enrollment."
Unmet Need in Biliary Tract Cancer (搜索)
Biliary tract cancer (搜索) has limited treatment options, particularly in the second-line setting. While targeted therapies exist for patients with certain genetic alterations, many patients do not have an actionable mutation and have limited options after first-line therapy. Cytotoxic chemotherapy can be used, but efficacy is modest and tolerability can be challenging.
Because nanvuranlat targets a metabolic dependency rather than a specific mutation, it may offer a new option for a broader patient population. Preclinical studies also suggest that combining nanvuranlat with an immune checkpoint inhibitor can enhance antitumor activity and increase immune-cell infiltration into tumors, a concept being evaluated in an investigator-initiated clinical trial in Japan.
Broader Pipeline and Future Directions
Beyond biliary tract cancer (搜索), nanvuranlat has shown preclinical activity in KRAS-mutant colorectal cancer (搜索), and J-Pharma is exploring academic collaborations to support clinical translation. The company's second clinical-stage compound, JPH034, is a brain-penetrant LAT1 inhibitor being developed for central nervous system disorders, with secondary progressive multiple sclerosis (搜索) as the lead indication. JPH034 entered a U.S. Phase 1 trial in March 2026, and subject to results and regulatory discussions, J-Pharma aims to initiate a Phase 2a proof-of-concept study in 2027.
J-Pharma's long-term goal is to become a globally recognized biotechnology company that translates transporter science into medicines with meaningful benefits for patients. Over the next decade, the company intends to advance its LAT1 inhibitor pipeline globally, obtain regulatory approvals, and deliver these therapies to patients worldwide.